SOHM, Inc., Receives a Mandate for Development, Manufacturing, and Supply Two New topical products.

Rhea-AI Summary

SOHM, Inc. (OTC PINK:SHMN) announced on August 4, 2021, that it has received a mandate for the development and manufacturing of two new human prescription topical products. The first product aims to treat hyperpigmentation, while the second is a combination medication for minor pain and discomfort related to hemorrhoids. SOHM anticipates that these products will be available in major pharmacy chains such as CVS and Wal-Mart by late Q3 or early Q4 2021. CEO Baron Night highlighted that this mandate represents an annualized commitment once the products are on the market.

Positive

• Received a mandate for two new prescription topical products.
• Products target significant healthcare issues: hyperpigmentation and hemorrhoid discomfort.
• Expected distribution through major pharmacy chains including CVS and Wal-Mart.

Negative

• None.

CHINO HILLS, CA / ACCESSWIRE / August 4, 2021 / SOHM, Inc. (the "Company") (OTC PINK:SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today (SOHM, Inc) the company, has received a mandate for development, manufacturing and supply for two new products for human prescription topical applications.

Today, Mr. Baron Night, CEO announce that, SOHM has received a Mandate from one of its customers for this latest opportunity to be a crucial part of two of the customer's new products. These products are human prescription products. The first of the two in use to lighten the dark patches of skin (also called hyperpigmentation, melasma, "liver spots," "age spots," freckles) caused by pregnancy, birth control pills, hormone medicine, or injury to the skin. This mechanism on how this medication functions is by blocking the process in the skin that leads to discoloration.

The Second product is a combination medication, which is used to treat minor pain, itching, swelling, and discomfort caused by hemorrhoids, and other problems of the anal area (e.g., anal fissures, itching). This medication contains an anesthetic that works by temporarily numbing the area. This product also contains corticosteroid that reduces redness, itching, and swelling.

Once it is developed and supplied, these mandates will be strengthening the company's efforts to continue its B2B business under a private label agreement. The company estimate the execution by end of the third or early 4^th quarter.

This mandate and scope of the project is just the beginning stages of launching more products into major pharmacy retail stores. SOHM's customer will be distributing them to various pharmacy chain stores that include Publix, CVS and Wal-Mart throughout the United States.

Mr. Baron Night, CEO said, "This represents an annualized commitment once this order is executed, and the product is on the shelf of pharmacies distribution and pharmacy retail stores".

About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a vision "Globalè Prospèro" that tries to build continuous growth. SOHM manufacturing and marketing targets the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India as well as has strategic alliances with US manufacturing facilities. Although SOHM's generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To know more about SOHM, Inc., visit www.SOHM.com

Safe Harbor Statement:
This news release contains "forward-looking statements", which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.

For more information, please contact:
SOHM, Inc.
714-522-6700

SOURCE: Sohm, Inc.

View source version on accesswire.com:
https://www.accesswire.com/658329/SOHM-Inc-Receives-a-Mandate-for-Development-Manufacturing-and-Supply-Two-New-topical-products

FAQ

What products has SOHM, Inc. received a mandate to develop?

SOHM, Inc. has received a mandate to develop two prescription topical products: one for hyperpigmentation and another for treating hemorrhoid-related discomfort.

When does SOHM expect to launch the new products?

SOHM anticipates the launch of the new products by the end of the third quarter or early fourth quarter of 2021.

Which pharmacy chains will distribute SOHM's new products?

The new products are expected to be distributed through major pharmacy chains including Publix, CVS, and Wal-Mart.

What is the significance of the mandate for SOHM, Inc.?

The mandate signifies an annualized commitment for SOHM once the products are executed and on pharmacy shelves, potentially boosting revenue.